Medtronic GuardWire Is First Distal Protection Device To Reach Panel Review
This article was originally published in The Gray Sheet
Executive Summary
PercuSurge's GuardWire Plus will be the first embolic protection device to undergo FDA panel review Feb. 5 when the Circulatory System Devices Panel evaluates the firm's PMA for saphenous vein graft applications.
You may also be interested in...
Abbott Entering Embolic Protection, Carotid Stent Markets Via MedNova
Abbott Labs is anticipating FDA approval of MedNova's CardioShield embolic filter device for saphenous vein graft applications in 2003, following a Feb. 2 announcement of an exclusive worldwide distribution agreement between the companies.
Abbott Entering Embolic Protection, Carotid Stent Markets Via MedNova
Abbott Labs is anticipating FDA approval of MedNova's CardioShield embolic filter device for saphenous vein graft applications in 2003, following a Feb. 2 announcement of an exclusive worldwide distribution agreement between the companies.
Distal Protection Device Promises Renal Applications, Amor's Study Suggests
The relatively low profile and maneuverability of the Medtronic/PercuSurge GuardWire distal protection system outweigh the disadvantages of total distal occlusion in renal angioplasty and stenting procedures, according to Max Amor, MD, chief of the Cardiology Clinic at Polyclinique Essey Les Nancy in France.